Ipamorelin

A selective pentapeptide ghrelin-receptor agonist, studied for its growth-hormone-secretagogue selectivity profile in pituitary research.

HPLC PURITY

99.6%

BATCH

#1903

9 vials

€51.64incl. 23% VAT · 10 mg

Buy more, save moreper unit

1+ unit€51.64

6+ units−7%€48.00

11+ units−15%€43.90

Wholesale or institutional quantities? Request a custom quote — we'll follow up to discuss.

Every batch is independently tested before it's listed — no exceptions.

COA PENDINGCertificate of analysis for batch #1903 is being uploaded — contact us if you need it before ordering.

For laboratory & research use only. Not for human or animal consumption.

Research background

Ipamorelin is a synthetic pentapeptide developed by Novo Nordisk in the late 1990s as a selective agonist of the growth hormone secretagogue receptor — the same receptor targeted by the hormone ghrelin. In preclinical studies, it triggers pulsatile growth hormone release from the pituitary that closely mirrors the body's natural secretion pattern, while showing minimal effect on cortisol, prolactin, or ACTH — a selectivity profile that distinguished it from earlier-generation GH-releasing peptides like GHRP-6. Because of this clean pharmacological profile, it has become a frequently used tool in research on growth-hormone-axis physiology and hypothalamic-pituitary signaling.

These statements have not been evaluated or certified by any regulatory authority. This product is not a drug, food, dietary supplement, or cosmetic, and is intended strictly for in-vitro laboratory and analytical research use by qualified institutions. It is not intended for human or animal use, consumption, diagnostic use, or therapeutic application of any kind.

References

Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. ↗

Reviews

No reviews yet. Verified buyers can leave a review from their account once an order is completed.